Mechanism of Action.
Semax is a synthetic heptapeptide consisting of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with a Pro-Gly-Pro (PGP) tripeptide that confers enzymatic stability. Despite its ACTH origin, semax does not produce steroidogenic or adrenal-stimulating effects at nootropic doses. Its primary mechanisms include upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, modulation of serotonergic and dopaminergic neurotransmission, enhancement of neuronal survival signaling through the MAPK/ERK and PI3K/Akt pathways, and anti-inflammatory effects through inhibition of pro-inflammatory cytokine expression. Semax also modulates the expression of over 100 genes in the hippocampus related to neuroplasticity and immune function. The PGP tripeptide itself has independent anti-inflammatory activity.
Research Summary.
Semax has been extensively studied in Russia, where it is an approved pharmaceutical for ischemic stroke, cognitive dysfunction, and optic nerve atrophy. Research demonstrates improvements in memory formation and consolidation, attention, learning capacity, and resistance to hypoxic brain damage. A key study showed that semax administration increased BDNF mRNA expression in the hippocampus and cerebral cortex by up to 4-fold. Studies in stroke patients showed accelerated neurological recovery and reduced infarct volume. Additional research has explored semax for ADHD, where it improved attention and reduced impulsivity in clinical assessments. The nootropic effects appear to involve enhanced long-term potentiation (LTP) and synaptic plasticity.
Side Effects & Safety.
Semax is generally considered to have a very favorable safety profile. In Russian clinical use over two decades, serious adverse events have been rare. The most commonly reported effects include mild nasal irritation with intranasal use and occasional headache. Because it does not significantly affect the HPA axis at nootropic doses, adrenal suppression is not a concern. No withdrawal symptoms, tolerance, or dependence have been reported. However, Western clinical trial data is limited, and most safety information comes from Russian pharmaceutical experience and preclinical research.
Legal Status & Access.
Semax is an approved prescription medication in Russia and several CIS countries for stroke recovery and cognitive enhancement. It is not FDA-approved in the United States and is classified as a Category 1 research peptide. It is available from research peptide suppliers for laboratory investigation. It is not a controlled substance.